ASGCT's Insight Series

Free Series for ASGCT Members

Join us January 25 and 26 for the first sessions of our ASGCT's Insight Series! The topics for this new series of virtual events are chosen jointly by two ASGCT committees whose collaboration will ensure programming unique from the Annual Meeting.

Each two-hour session will be free for ASGCT members and $50 for non-members. Learn more about them and register below. 

Upcoming Sessions

Jan. 25: Clinical Aspects and Immune Responses in Patients with Long COVID

This session seeks to provide a better understanding of long COVID-19, which affects about 10% of patients who become infected with SARS-CoV-2. Speakers will discuss the pathogenesis, clinical aspects, and immune responses, of COVID-19 and long COVID.

Each session is free for ASGCT members and $50 for non-members.

Jan. 26: Finding a Good Match - Landing a Perfect Position in an International Lab

American PIs will learn about the importance of bringing international trainees to their labs. Early career investigators will share their experiences in transitioning to working for U.S.-based academic institutions. Attendees will learn best practices around finding employment and hiring non-U.S. based PhD students and postdoctoral fellows to the U.S.

Each session is free for ASGCT members and $50 for non-members.

Feb. 16: AAV Vector Design

Speakers will discuss cutting-edge concepts and methods in the design and development of AAV vectors.

Each session is free for ASGCT members and $50 for non-members.

Feb. 23: Immune Responses to Gene Therapy for Musculo-Skeletal and Cardiac Diseases

This session highlights the ongoing research related to the administration of high-dose adeno-associated virus (AAV) in patients with an emphasis on safety and tolerability findings.

Each session is free for ASGCT members and $50 for non-members.

2022

ASGCT 25th Annual Meeting

May 16-19, 2022

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.